Rhesus IL-8/CXCL8 recombinant protein

Cat.#: 504784

Size:

Special Price 148.5 USD

Availability: In Stock
- +

Add to cart to get an online quotation

Product Information

  • Product Name
    Rhesus IL-8/CXCL8 recombinant protein
  • Documents
  • Description
    Interleukin 8 (IL-8), also known as CXCL8, which is a chemokine with a defining CXC amino acid motif that was initially characterized for its leukocyte chemotactic activity, is now known to possess tumorigenic and proangiogenic properties as well. This chemokine is secreted by a variety of cell types including monocyte/macrophages, T cells, neutrophils, fibroblasts, endothelial cells, and various tumor cell lines in response to inflammatory stimuli (IL1, TNF, LPS, etc). In human gliomas, IL-8 is expressed and secreted at high levels both in vitro and in vivo, and recent experiments suggest it is critical to glial tumor neovascularity and progression. Levels of IL-8 correlate with histologic grade in glial neoplasms, and the most malignant form, glioblastoma, shows the highest expression in pseudopalisading cells around necrosis, suggesting that hypoxia/anoxia may stimulate expression. Interleukin (IL)-8/CXCL8 is a potent neutrophil chemotactic factor. Accumulating evidence has demonstrated that various types of cells can produce a large amount of IL-8/CXCL8 in response to a wide variety of stimuli, including proinflammatory cytokines, microbes and their products, and environmental changes such as hypoxia, reperfusion, and hyperoxia. Numerous observations have established IL-8/CXCL8 as a key mediator in neutrophil-mediated acute inflammation due to its potent actions on neutrophils. However, several lines of evidence indicate that IL-8/CXCL8 has a wide range of actions on various types of cells, including lymphocytes, monocytes, endothelial cells, and fibroblasts, besides neutrophils. The discovery of these biological functions suggests that IL-8/CXCL8 has crucial roles in various pathological conditions such as chronic inflammation and cancer. IL-8 has been associated with tumor angiogenesis, metastasis, and poor prognosis in breast cancer. IL-8 may present a novel therapeutic target for estrogen driven breast carcinogenesis and tumor progression.
  • Uniprot ID
    P67813
  • Source/Expression Host
    E. coli
  • Expression Plasmid/cDNA
    A DNA sequence encoding the rhesus IL8 (NP_001028137.1)(Ala23-Pro101) was expressed and purified with an initial Met.
  • Protein Species
    Rhesus
  • Molecular weight
    The recombinant rhesus IL8 consists of 80 amino acids and has a calculated molecular mass of 9.3 KDa.
  • Purity
    > 95 % as determined by SDS-PAGE
  • Activity
    Measured by its binding ability in a functional ELISA.
    Immobilized Rhesus IL8 (Cat:504784) at 10 μg/mL (100 μl/well) can bind biotinylated human RELA-GST (Cat:501219). The EC50 of biotinylated human RELA-GST (Cat:501219) is 0.5-1.2 μg/mL.
  • Validations

    Cynomolgus IL-8 / CXCL8 Protein SDS-PAGE

    Cynomolgus IL-8 / CXCL8 Protein SDS-PAGE

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"